Productos disponibles

Comercial Nombre genérico Prescribir
OxyContin® Oxycodone Información para prescribir
OxyNorm® Oxycodone
MST Continus® Morphine Información para prescribir
Targin® Oxycodone / Naloxone
Sovenor® Buprenorphine
Restiva® Buprenorfina Información para prescribir
Hay productos adicionales en esta área de terapia disponibles entre la red de empresas independientes de Mundipharma en Asia Pacífico, América Latina, Oriente Medio y África que actualmente no están registradas en Singapur. Tenga en cuenta que algunos de estos productos tienen otros nombres en diferentes jurisdicciones.
Comercial Nombre genérico Prescribir
Cosopt® Dorzolamida-Timolol
Saflutan® Tafluprost
Trusopt® Dorzolamida
Timoptic® Timolol
Hay productos adicionales en esta área de terapia disponibles entre la red de compañías asociadas independientes de Mundipharma en Asia Pacífico, América Latina, Medio Oriente y África que actualmente no están registradas en Singapur. Tenga en cuenta que algunos de estos productos tienen otros nombres en diferentes jurisdicciones
Comercial Nombre genérico Prescribir
Flutiform® Fluticasone Propionate / Formoterol Fumarate Dihydrate Información para prescribir
Hay productos adicionales en esta área de terapia disponibles entre la red de compañías asociadas independientes de Mundipharma en Asia Pacífico, América Latina, Medio Oriente y África que actualmente no están registradas en Singapur. Tenga en cuenta que algunos de estos productos tienen otros nombres en diferentes jurisdicciones

Analgesia

Our responsibility in opioid management

The Mundipharma network of independent associated companies has a proud heritage in pain management and is committed to enabling healthcare professionals to treat their patients in pain safely and responsibly. As a network that manufactures opioids, we believe we have a responsibility to take measures to minimize the risk of misuse and abuse of these medicines, while not depriving the patients that need them.

As a network, we recognize that misuse and abuse of pain medications can lead to addiction, overdose and death, and we are aware of the public health risk these potent medications can create, especially when they are diverted, misused and/or abused. That is why we are committed to reducing the risk of misuse and abuse through a secure supply chain, appropriate education of healthcare professionals, responsible sales and marketing practices and close collaboration with government authorities and medical organizations.

We fund educational initiatives in line with industry regulations that clearly communicate the facts about opioid medicines in a balanced and responsible manner, outlining both risks and benefits and helping to ensure that our medicines are prescribed only to the right patient for the right reasons.

We are also committed to finding new approaches to the management of pain, including research into new mechanisms and medicines with the potential to reduce or avoid the need for opioids.

Ophthalmology

Mundipharma confirms its commitment to more than 66 million people in the world suffering from Glaucoma. By purchasing Merck Sharp Dohme (MSD) ophthalmology products in more than 54 countries, the company manages to position itself in leadership positions with medicines of recognized trajectory and quality for the treatment of this pathology.

Pioneers in the health and care of the human being. Innovative medicine made accessible to those who need it

Respiratory

Mundipharma strengthens its portfolio by offering medicines for the treatment of asthma; One of the most common chronic diseases in the world, associated with high mortality rates.
Introducing to the Argentine market this new and unique therapeutic option in asthma, we are sure to contribute to better control of the disease.

Oncology

Onco-Hematology

Mundipharma offers new opportunities in the treatment of lymphomas.

Lymphomas are diseases of the blood system that are serious and potentially deadly. Peripheral T-cell lymphomas are conditions that, although rare, are of poor prognosis. Mundipharma has in its portfolio the first product approved by the American Regulatory Agency (FDA) for the treatment of this disease offering a therapeutic option.

Others Specialities